Literature DB >> 31594704

Effects of Chronic Kidney Disease on Hemiarthroplasty Outcomes for Fragility Hip Fracture in Diabetic Patients: A Nationwide Population-Based Observational Study.

Su-Ju Lin1, Tien-Hsing Chen2, Liang-Tseng Kuo3, Pei-An Yu4, Chi-Lung Chen4, Wei-Hsiu Hsu3.   

Abstract

BACKGROUND: The aim of this study is to compare perioperative outcomes, readmission, and mortality after hemiarthroplasty for hip fractures in diabetic patients with different renal function statuses.
METHODS: In this retrospective population-based cohort study, diabetic patients who received primary hemiarthroplasty for hip fracture between January 1997 and December 2013 were identified from the Taiwan National Health Insurance Research Database. Primary outcomes were perioperative outcomes including infection and revision. Secondary outcomes were all-cause readmission and mortality.
RESULTS: A total of 29,535 diabetic patients were included: 8270 patients had chronic kidney disease (CKD group), 1311 patients underwent permanent dialysis (dialysis group), and 19,954 patients did not have CKD (non-CKD group). During a mean follow-up of 4.5 years, these 3 groups had comparable risks of any infection, including superficial and deep infection. Dialysis patients had a significantly higher risk of revision than did CKD and non-CKD patients (subdistribution hazard ratio 1.65, 95% confidence interval 1.16-2.36; subdistribution hazard ratio 1.57, 95% confidence interval 1.10-2.24, respectively). Compared with the non-CKD group, the dialysis group had significantly higher risks of readmission and mortality at all time points, namely 3 months after surgery, 1 year after surgery, and the final follow-up. The CKD group also had higher risks of readmission and mortality than did the non-CKD group at all time points.
CONCLUSION: CKD is associated with poor outcomes following hemiarthroplasty for fragility hip fracture. CKD patients may have higher risks of surgical complications including revision than non-CKD patients, and they have significantly elevated risks of readmission and mortality.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic kidney disease; diabetes mellitus; hemiarthroplasty; hip fracture; mortality; readmission

Year:  2019        PMID: 31594704     DOI: 10.1016/j.arth.2019.09.016

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  5 in total

1.  Application of Different Doses of Tranexamic Acid Plus Traditional Chinese Medicine in Hip Arthroplasty in Patients with Diabetes and Its Influence on Intraoperative Blood Loss and Postoperative Drainage.

Authors:  Xiao-Long Yang; Bei Luo; Zhong-Xing Zhang; Xiao-Feng Feng; Feng Xu
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-17       Impact factor: 2.650

2.  Morbidity after elective surgery in patients on chronic dialysis: a systematic review and meta-analysis.

Authors:  Dharmenaan Palamuthusingam; Arun Nadarajah; David Wayne Johnson; Elaine Marie Pascoe; Carmel Marie Hawley; Magid Fahim
Journal:  BMC Nephrol       Date:  2021-03-18       Impact factor: 2.388

3.  Hip fracture in patients with non-dialysis chronic kidney disease stage 5.

Authors:  Chao-Hsiun Tang; Che-Yi Chou
Journal:  Sci Rep       Date:  2021-10-18       Impact factor: 4.379

4.  Chronic Kidney Disease Is Associated with High Mortality Risk in Patients with Diabetes after Primary Shoulder Arthroplasty: A Nationwide Population-Based Cohort Study.

Authors:  Meng-Hao Lin; Su-Ju Lin; Liang-Tseng Kuo; Tien-Hsing Chen; Chi-Lung Chen; Pei-An Yu; Yao-Hung Tsai; Wei-Hsiu Hsu
Journal:  Diagnostics (Basel)       Date:  2021-05-01

5.  The impact of systemic lupus erythematosus on the risk of infection after total hip arthroplasty: a nationwide population-based matched cohort study.

Authors:  Chien-Hao Chen; Tien-Hsing Chen; Yu-Sheng Lin; Dave W Chen; Chi-Chin Sun; Liang-Tseng Kuo; Shih-Chieh Shao
Journal:  Arthritis Res Ther       Date:  2020-09-14       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.